Cardiac involvement is well recognised in most forms of the mucopolysaccharidoses but
The mucopolysaccharidoses are one class of lysosomal storage disease produced by an inherited absence or defective activity of one of the enzymes involved in the degradation of a group of complex polysaccharides known as glycosaminoglycans. Intralysosomal accumulation of glycosaminoglycans results in progressive disability due to differing degrees of involvement of connective tissue and ground substance with predominant involvement of the skeletal system. Mucopolysacchariduria is a characteristic feature and detection of the specific glycosaminoglycan in the urine aids diagnosis. To date, eight separate types of mucopolysaccharidoses have been identified based on the specific lysosomal enzyme deficiency and each type has distinct clinical features leading to eponymous syndromes. Type IV mucopolysaccharidosis was described in 1929 by Morquio in Uruguay and Brailsford in England, and is due to defective catabolism of keratan sulphate and chondroitin sulphate. Two forms of the disease has been described. The classic form (type A) is due to deficiency of Nacetylgalactosamine 6- The two patients (9 and 10), who had both mitral and aortic valve disease, also had myocardial abnormalities. These were biventricular concentric hypertrophy in patient 10 ( fig 3) and left ventricular apical hypertrophy in patient 9. Pulsed Doppler trace on the left ventricular inflow in patient 10 showed a higher flow velocity during atrial systole which suggests a degree of restriction of left ventricular filling. Although most of these patients will be poor candidates for mnajor cardiac surgery, orthopaedic intervention will be necessary at some stage, usually in childhood. Haemodynamically their cardiac abnormalities are unlikely to be important in the context of surgery, but the high prevalence of valvular abnormalities found in this study suggests that antibiotic prophylaxis against infective endocarditis is indicated.
